Woodline Partners’s Olema Oncology OLMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.08M Sell
588,030
-163,000
-22% -$1.78M 0.02% 713
2026
Q2
$9.4M Sell
751,030
-731,000
-49% -$9.8M 0.03% 549
2026
Q1
$22.1M Buy
1,482,030
+100
+0% +$2.23K 0.08% 317
2025
Q4
$37M Sell
1,481,930
-735,963
-33% -$13.1M 0.14% 183
2025
Q3
$21.7M Sell
2,217,893
-1,288,000
-37% -$7.73M 0.1% 264
2025
Q2
$14.9M Buy
3,505,893
+2,027,986
+137% +$9.04M 0.08% 349
2025
Q1
$5.56M Buy
1,477,907
+120,428
+9% +$606K 0.04% 481
2024
Q4
$7.91M Buy
1,357,479
+3,293
+0.2% +$32.9K 0.05% 397
2024
Q3
$16.2M Buy
1,354,186
+501,632
+59% +$6.41M 0.14% 216
2024
Q2
$9.22M Buy
852,554
+102,275
+14% +$1.11M 0.09% 258
2024
Q1
$8.49M Hold
750,279
– – 0.08% 294
2023
Q4
$10.5M Buy
750,279
+32,947
+5% +$443K 0.11% 224
2023
Q3
$8.86M Buy
717,332
+129,280
+22% +$1.32M 0.1% 238
2023
Q2
$5.31M Buy
+588,052
New +$3.55M 0.06% 279

Other funds holding OLMA

Woodline Partners's OLMA Position: Q3 2026 in Review

Woodline Partners reduced its Olema Oncology (OLMA) stake by 22% in Q3 2026, selling an estimated $1.78M and leaving 588,030 shares worth $5.08M. The position accounts for 0.02% of the portfolio, ranked #713.

Woodline Partners first reported a position in OLMA in Q2 2023 and has held it in 14 quarters since. The position peaked at $37M in Q4 2025. 177 funds tracked by Wall St. Rank hold OLMA as of Q3 2026.

  • Woodline Partners held 588,030 shares of Olema Oncology worth $5.08M as of Q3 2026.
  • Woodline Partners sold 163,000 Olema Oncology shares in Q3 2026, an estimated $1.78M.
  • Olema Oncology made up 0.02% of Woodline Partners's portfolio in Q3 2026, its #713 holding.
  • Woodline Partners first reported a position in Olema Oncology in Q2 2023 and has held it in 14 quarters since.
  • Woodline Partners's Olema Oncology position peaked at $37M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Olema Oncology as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.